Loading...
XNYS
BHC
Market cap1.82bUSD
Jul 10, Last price  
4.78USD
1D
-1.02%
1Q
-13.21%
Jan 2017
-66.53%
Name

Bausch Health Companies Inc

Chart & Performance

D1W1MN
XNYS:BHC chart
P/E
11.18
P/S
0.17
EPS
0.43
Div Yield, %
Shrs. gr., 5y
1.10%
Rev. gr., 5y
5.41%
Revenues
10.45b
+8.53%
1,070,475,000842,818,000757,178,000820,430,0001,146,128,0002,463,450,0003,480,400,0005,765,600,0008,200,000,00010,442,000,0009,674,000,0008,724,000,0008,380,000,0008,601,000,0008,027,000,0008,434,000,0008,124,000,0008,757,000,0009,625,000,00010,445,711,808
Net income
160m
P
210,004,059195,539,000199,904,000176,455,000-208,193,000159,559,000-116,025,000-866,142,000881,000,000-268,658,802-2,409,000,0002,404,000,000-4,148,000,000-1,783,000,000-559,000,000-948,000,000-225,000,000-592,000,000-46,000,000159,748,368
CFO
1.40b
-12.34%
521,934,000340,853,000204,325,000360,897,000263,191,000676,473,000656,578,0001,041,957,0002,294,700,0002,200,400,0002,087,000,0002,290,000,0001,501,000,0001,501,000,0001,111,000,0001,426,000,000-728,000,0001,032,000,0001,597,000,0001,400,000,000
Dividend
Nov 10, 20101 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Bausch Health Companies Inc. is a global healthcare enterprise dedicated to the creation, production, and sale of a diverse array of pharmaceutical, medical device, and over-the-counter items. Its primary therapeutic focus areas include eye health, digestive system issues, and dermatological conditions. The company's operations are strategically organized into five key divisions: Bausch + Lomb, which specializes in vision care, surgical solutions, and ophthalmic pharmaceuticals; Salix, concentrating on gastroenterology products within the United States; International Rx, offering a broad portfolio encompassing Solta products, branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across numerous international markets in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East; Ortho Dermatologics, providing dermatological products in the U.S. and Solta medical aesthetic devices globally; and Diversified Products, covering pharmaceutical products in neurology and other therapeutic classes, alongside generic and dentistry items in the United States. Previously known as Valeant Pharmaceuticals International, Inc., the company adopted its current name in July 2018 and maintains its headquarters in Laval, Canada.
IPO date
Sep 20, 1994
Employees
19,900
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT